Max Robotics — Global Service Robot Directory + US Certification

About

Marc Zerbib is a leading French urologic oncologist whose research focuses on the surgical and economic dimensions of prostate and kidney cancer treatment. His work has been instrumental in evaluating the comparative effectiveness and cost-efficiency of emerging technologies in urologic oncology. Zerbib’s most influential study, “Conventional Treatments of Localized Prostate Cancer” (2008, 53 citations), provides a foundational analysis of standard therapeutic approaches. He has also been a key voice in the debate over robotic surgery, notably in “Will Robotic Surgery Become the Gold Standard for Radical Prostatectomy?” (2006, 47 citations), which critically assessed the trajectory of minimally invasive techniques. His contributions extend to renal cancer, with a landmark multicenter study on partial nephrectomy (2014, 31 citations) that shaped contemporary surgical practice. More recently, Zerbib has pioneered health-economic analyses, including a 2022 cost-utility study comparing robot-assisted surgery and stereotactic body radiotherapy for prostate cancer. Through his prospective multicenter trials and medico-economic research, Zerbib has provided crucial evidence for optimizing treatment pathways, balancing clinical outcomes with healthcare costs, and guiding the adoption of robotic technologies in France and beyond.